Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsDaniel Jacoby, MD
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Biography
Dr. Daniel Jacoby specializes in the diagnosis and treatment of heart failure and cardiomyopathy.
Dr. Jacoby is the Founder and Director of the premier Cardiomypathy Program in the region, dedicated to serving the needs of patients, and families, living with the diagnosis of cardiomyopathy. Expert diagnosis and treatment of hypertrophic, dilated, arrhythmogenic and restrictive cardiomyopathies, as well as evaluation for causes of sudden cardiac death, are available through the Cardiomyopathy Program.
Dr. Jacoby has contributed widely to the literature of both heart failure and cardiomyopathy.
He serves as the Clinical Director of Innovation for Yale New Haven Health System. In this role Dr. Jacoby provides clinically oriented leadership for mission aligned bio-tech for internal and external partnerships and investments.
Last Updated on July 15, 2024.
Appointments
Cardiovascular Medicine
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Adult Congenital Heart Program
- Cardiovascular Medicine
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Ventures
Education & Training
- Fellow
- Columbia Presbyterian Hospital (2007)
- Chief Fellow
- Columbia Presbyterian Hospital (2007)
- Resident
- Mount Sinai Hospital (2004)
- Chief Resident
- The Mount Sinai Hospital (2004)
- MD
- Yale School of Medicine (2000)
- BA
- Yale College, Judaic Studies (1993)
Research
Copy Link
Overview
Medical Research Interests
Amyloidosis; Clinical Trial; Genetics; Heart Failure; Heart Transplantation; Sleep
ORCID
0000-0002-9182-275X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Daniel Jacoby's published research.
Publications Timeline
A big-picture view of Daniel Jacoby's research output by year.
Research Interests
Research topics Daniel Jacoby is interested in exploring.
Sangchoon Jeon, PhD
Tariq Ahmad, MD, MPH
Christopher Maulion, MD
Edward J Miller, MD, PhD
Nancy Schmieder Redeker, RN, MSN, PhD, FAHA, FAAN
Harlan Krumholz, MD, SM
102Publications
6,077Citations
Heart Failure
Heart Transplantation
Sleep
Amyloidosis
Publications
2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Campain J, Griskowitz C, Newlands C, Claggett B, Kulac I, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats C, Lee M, Maron M, Owens A, Jacoby D, Heitner S, Kupfer S, Malik F, Wohltman A, Malhotra R, Lewis G. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. Circulation 2025 PMID: 40910168, DOI: 10.1161/circulationaha.124.073585.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCardiopulmonary exercise testingPeak VOObstructive hypertrophic cardiomyopathyLeft ventricular outflow tract gradientExercise testOutflow tract gradientCardiopulmonary exercise test protocolsExercise test protocolPrimary outcomeDisease-specific treatmentHypertrophic cardiomyopathyCardiac performanceCardiac functionTreatment of obstructive hypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyLongitudinal measurementsHigh-sensitivity cardiac troponin IPeripheral oxygen extractionEvent-free survivalHeart failure hospitalizationHazard ratioAll-cause deathAdvanced heart failureReferral cohortCardiac troponin ILow Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials
Rowin E, Maron M, Olivotto I, Coats C, Abraham T, Nassif M, Barriales-Villa R, Saberi S, Heitner S, Jacoby D, Kupfer S, Malik F, Simkins T, Wei J, Masri A, REDWOOD-HCM S. Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials. Heart Rhythm 2025 PMID: 40897259, DOI: 10.1016/j.hrthm.2025.08.031.Peer-Reviewed Original ResearchAltmetricAficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Garcia-Pavia P, Maron M, Masri A, Merkely B, Nassif M, Peña-Peña M, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel J, Correia E, Dybro A, Elliott P, Hegde S, Lakdawala N, Lewis G, Mann A, Miao Z, Nair A, Poulsen S, Reant P, Schulze P, Solomon S, Wang A, Sohn R, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Wohltman A, Fifer M. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. New England Journal Of Medicine 2025, 393: 949-960. PMID: 40888697, DOI: 10.1056/nejmoa2504654.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLeft ventricular outflow tract gradientSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientObstructive hypertrophic cardiomyopathyLeft atrial volume indexLeft ventricular mass indexAtrial volume indexVentricular mass indexHypertrophic cardiomyopathyPeak oxygen uptakeKCCQ-CSSMetoprolol monotherapyMetoprolol groupNT-proBNPValsalva maneuverBeta-blockersKansas City Cardiomyopathy Questionnaire clinical summary scoreMass indexN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideVolume indexDouble-dummy trialNT-proBNP levelsSecondary end pointsCardiac myosin inhibitorEffect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM
Hegde S, Wang X, Garcia-Pavia P, Getchevski S, Masri A, Merkely B, Nassif M, Peña-Peña M, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Maron M, Nair A, Poulsen S, Reant P, Schulze P, Wang A, Sohn R, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Wohltman A, Fifer M, Solomon S, Investigators M. Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. Journal Of The American College Of Cardiology 2025 PMID: 40932433, DOI: 10.1016/j.jacc.2025.08.022.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLeft ventricular ejection fractionSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyMitral valve systolic anterior motionLeft atrial volume indexAtrial volume indexSystolic anterior motionEffects of monotherapyHypertrophic cardiomyopathyAnterior motionDiastolic functionMitral regurgitationCardiac structureMeasures of LV diastolic functionLV global longitudinal strainVolume indexEchocardiographic measures of cardiac structureMeasures of cardiac structureOutflow tract gradientLV diastolic functionFirst-line therapyGlobal circumferential strainGlobal longitudinal strainVentricular ejection fractionMaximal wall thicknessHealth Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation.
Stendahl J, Sen S, Butzner M, Papademetriou E, Potluri R, Liu X, Jacoby D, Freeman J. Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation. Journal Of The American Heart Association 2025, 14: e038755. PMID: 40847492, DOI: 10.1161/jaha.124.038755.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyHealth care resource useCare resource useHealth care costsAtrial fibrillationTotal health care costsIncident AFCare costsHypertrophic cardiomyopathyRetrospective analysisSeptal reduction therapyGreater health care costsRetrospective analysis of claims dataDiagnosis of AFImpact of AFResource useAnalysis of claims dataAdult patientsReduction therapyPatient managementUrgent carePatientsClaims dataCardiomyopathyToward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling
Xu D, Li H, Heitner S, Jacoby D, Kupfer S, German P, Lutz J. Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling. CPT Pharmacometrics & Systems Pharmacology 2025 PMID: 40820573, DOI: 10.1002/psp4.70099.Peer-Reviewed Original ResearchConceptsLower AUCMale patientsHypertrophic cardiomyopathyObstructive HCMPopulation pharmacokineticsBody weightApparent volumeInterindividual variabilityApparent intercompartmental clearanceObstructive hypertrophic cardiomyopathyCardiac myosin inhibitorPopulation pharmacokinetic modelBaseline body weightChronic oral treatmentPopulation PK analysisTime to steady stateLow interindividual variabilityPredicting PK profilesStatistically significant covariatesApparent clearanceAficamtenFemale patientsPK analysisOral treatmentLinear eliminationAficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy 48-Week Results From FOREST-HCM
Saberi S, Abraham T, Choudhury L, Barriales-Villa R, Elliott P, Nassif M, Oreziak A, Owens A, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats C, Fifer M, Sherrid M, Solomon S, Watkins H, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Meng L, Wei J, Maron M, Masri A, Committee and Investigators F. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy 48-Week Results From FOREST-HCM. JACC Heart Failure 2025, 13: 102496. PMID: 40540987, DOI: 10.1016/j.jchf.2025.03.040.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLeft ventricular ejection fractionOutflow tract gradientVentricular ejection fractionEjection fractionKansas City Cardiomyopathy Questionnaire-Clinical Summary ScorePeak left ventricular outflow tract gradientLeft ventricular outflow tract gradientMaximum left ventricular wall thicknessSymptomatic obstructive hypertrophic cardiomyopathyLeft atrial volume indexWeeks of follow-upAtrial volume indexObstructive hypertrophic cardiomyopathyFunctional class improvementLeft ventricular wall thicknessBaseline to weekFavorable cardiac remodelingNYHA functional class improvementRelief of obstructionCardiac biomarker levelsVentricular wall thicknessLong-term safetyDrug discontinuationLateral E/eOpen-labelEfficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial
Maron M, Gimeno J, Veselka J, Barriales-Villa R, Claggett B, Coats C, Hegde S, Januzzi J, Kulac I, Masri A, Nassif M, Spertus J, Jacoby D, Heitner S, Kupfer S, Malik F, Wohltman A, Olivotto I. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. European Heart Journal 2025, ehaf364. DOI: 10.1093/eurheartj/ehaf364.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObstructive hypertrophic cardiomyopathyNew York Heart AssociationNew York Heart Association classKCCQ-CSSSecondary endpointsHypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire clinical summary scoreTreatment-emergent serious adverse eventsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideMild symptomsOutflow tract gradientBaseline to weekModerate to severe symptomsClinical summary scoreSerious adverse eventsSymptom groupsClinically relevant outcomesPeak oxygen uptakePrimary endpointSymptomatic patientsNT-proBNPStatistically significant improvementNatriuretic peptideAficamtenAcoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
Masri A, Aras M, Grogan M, Jacoby D, Maurer M, Shah S, Witteles R, Wong P, Ji A, DU J, Siddhanti S, Katz L, Sinha U, Fox J, Judge D. Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up. Journal Of Cardiac Failure 2025, 31: 1354-1359. PMID: 40216220, DOI: 10.1016/j.cardfail.2025.03.017.Peer-Reviewed Original ResearchCitationsAltmetricConcomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Masri A, Maron M, Abraham T, Nassif M, Barriales-Villa R, Bilen O, Coats C, Elliott P, Garcia-Pavia P, Massera D, Olivotto I, Oreziak A, Owens A, Saberi S, Solomon S, Tower-Rader A, Heitner S, Jacoby D, Melloni C, Wei J, Sherrid M, Olivotto I, Michels M, Barriales-Villa R, Garcia-Pavia P, Abraham T, Choudhury L, Kramer C, Lakdawala N, Maron M, Masri A, Nagueh S, Owens A, Rader F, Saberi S, Sherrid M, Symanski J, Tower-Rader A, Turer A, Wang A, Wong T, Zhang Y, Yang H, Shao C, Yuan Z, Zeng Q, Li X, Ma C, Wang Y, Shu Y, Chen M, Tao L, Li X, Wang J, Yu Z, Cheng X, Hong K, Zemanek D, Bundgaard H, Thune J, Jensen M, Mogensen J, Hagège A, Habib G, Charron P, Lhermusier T, Trochu J, Reant P, Logeart D, Mitrovic V, Bekfani T, Edelman F, Seidler T, Meder B, Schulze P, Stoerk S, Rassaf T, Merkely B, Zfat-Zwas D, Arad M, Halabi M, Paz O, Piltz X, Targetti M, Metra M, Canepa M, Musumeci B, Emdin M, Michels M, Amin A, Knackstedt C, Oreziak A, Wojakowski W, Dudek D, Toste A, Bastos J, Barriales-Villa R, Pavia P, Gimeno Blanes J, Hidalgo Urbano R, Alvarez A, Rincón Diaz L, Ripoll Vera T, Elliott P, Coats C, Cooper R, Mahmod M, Bradlow W, Pantazis A, Tome Esteban M, Masri A, Nassif M, Marian A, Owens D, Wheeler M, McGrew F, Bach R, Wever-Pinzon O, Collado E, Turer A, Hannawi B, Geske J, Owens A, Symanski J, Kramer C, Sarswat N, Ahmad F, Abraham T, Markowitz J, Lakdawala N, Choudhury L, Jani S, Brinkley D, Bilen O, Asher C, Emani S, Sharma A, Fermin D, Lyle M, Raymer D, Darlington A, Maron M, Nielsen C, Wang A, Nagueh S, Martinez M, Desai M, Tower-Rader A, Kelly J, Rader F, Sen S, Bering P, Maurer M, Mitter S, Sherrid M, Wong T, Hussain Z, Saberi S, Naidu S, Enciso J, Zemanek D, Bundgaard H, Jensen M, Mogensen J, Thune J, Donal E, Habib G, Hagege A, Logeart D, Reant P, Trochu J, Brandenburg S, Edelman F, Meder B, Rassaf T, Schulze P, Stoerk S, Merkely B, Arad M, Halabi M, Piltz X, Zfat-Zwas D, Emdin M, Musumeci B, Knackstedt C, Michels M, Oreziak A, Wojakowski W, Bastos J, Toste A, Bradlow W, Coats C, Cooper R, Elliott P, Pantazis A, Raman B, Tome Esteban M, Abraham T, Afshar K, Alsidawi S, Bering P, Bilen O, Brinkley D, Choudhury L, Darlington A, Desai M, Drakos S, Hannawi B, Hussain Z, Kelly J, Kramer C, Lakdawala N, Martinez M, Masri A, Mitter S, Moss N, Nagueh S, Naidu S, Nassif M, Owens A, Rader F, Ravi S, Rowin E, Saberi S, Sen S, Sherrid M, Enciso J, Rader A, Turer A, Wang A, Weiner S, Wong T, Zenker M. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure 2025, 102441. PMID: 40285763, DOI: 10.1016/j.jchf.2025.03.008.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyLeft ventricular outflow tractLVOT obstructionOpen-labelHypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathy patientsPlacebo add-on therapyEfficacy of concomitant useEpisodes of atrial fibrillationVentricular outflow tractAdd-on therapyCardiac myosin inhibitorCohort of patientsNegative inotropic propertiesWorsening of symptomsDisopyramide doseBackground therapyPlacebo-ControlledCombination therapyNT-proBNPOutflow tractAficamtenConcomitant useClinical efficacy
Academic Achievements & Community Involvement
Copy Link
Activities
activity Section of Cardiovascular Disease Fellowship Training Program
2010 - PresentCommitteesMemberDetailsParticipate in candidate interview and selection processactivity Pediatric Cardiology Chief Search Committee
2011 - PresentCommitteesMemberDetailsReviewed candidate options. Interviewed candidates. Provided feedback and participated in debate and discussion in the selection of the Pediatric Cardiology Chief position.activity Quality Assurance and Process Improvement Committee Co-Chair
02/01/2014 - PresentCommitteesCo-ChairDetailsReview regulatory and quality metrics. Guide program through regulatory visits. Identify and improve on existing program structure for growth, quality, and efficiency. Solicit input from faculty and staff regarding program function. Establish metrics for dashboard population and review. Supervise development of internal metrics dashboard. Report out to Yale New Haven Transplant Center Quality Assessment and Process Improvement meeting.activity Advanced Heart Failure Recipient Review Committee Co-Chair
02/01/2014 - PresentCommitteesCo-ChairDetailsOrganize structure and process around recipient review for advanced heart failure therapies (left ventricular assist devices and heart transplant). Arbitrate and act as final decision maker with Co-Chair (Surgical Director of Advanced Heart Failure) regarding transplant listing and device implant decisions for patients brought up for consideration. Supervise nursing and coordinator staff in recipient evaluation. Review any and all issues that arise in the course of the week regarding transplant listed patients. Establish and maintain heart transplant and LVAD protocols and pathways.activity Clinical Operations Committee - Section of Cardiovascular Diseases
2018 - PresentCommitteesMemberDetailsRepresent the Comprehensive Heart Failure Program contributing to Cardiovascular Disease Section initiatives and clinical operations planning. Participate in Section vision and mission discussions particularly regarding clinical operations and contribute meaningful, actionable plans and perspectives to support and grow the Section of Cardiovascular Diseases on behalf of the faculty, staff, and patients we serve.
Honors
honor Teacher of the Year
05/01/2008Yale School of Medicine AwardYale New Haven Hospitalist ProgramDetailsUnited Stateshonor Humanism in Medicine
06/15/2004Other AwardAlpha Omega AlphaDetailsUnited States
News
Copy Link
Get In Touch
Copy Link